Replies to post #211 on Endocyte Inc fka ECYT

[bob smith]

thanks for the update of ownership.


gl

[surf1944]

7:31AM Endocyte: New published data demonstrate co's targeted small molecule drug conjugate approach shows 'promising' results in polycystic kidney disease model (ECYT) 7.88 : Co announced that Endocyte's approach of utilizing a SMDC targeted to the folate receptor may provide a promising treatment for patients with autosomal-dominant polycystic kidney disease. In a mouse model of polycystic kidney disease, treatment with a folate-conjugated form of rapamycin, FC-rapa, (EC0371) strongly attenuated proliferation and growth of renal cysts and preserved renal function. The results were published online ahead of print in the Journal of the American Society of Nephrology and will be available in print in the October issue. Endocyte chemically synthesized EC0371 by linking the folic acid targeting ligand with the rapamycin drug payload. Rapamycin, a potent inhibitor of mTOR, is a promising drug for PKD therapy. The mTOR pathway is deregulated in ADPKD, and its inhibition reverses renal cystogenesis in animal models. However, in previous clinical trials treatment was limited by the amount of the untargeted rapamycin that could be safely administered. The membranes of both human and mouse PKD cysts were found to express the FR, which is the target of the EC0371's high affinity ligand. Results of this study showed that EC0371 inhibits the mTOR pathway activity in a dose- and FR-dependent manner.